Navigating Executive Orders and DOJ Memos That Threaten Criminal Prosecution
FDA Law Blog
MAY 26, 2025
Even if otherwise truthful, the promotion of off-label uses of hormones-including through informal campaigns like those conducted by sales reps or under the guise of sponsored continuing medical education courses-run afoul of the FDAs prohibitions on misbranding and mislabeling. 118, 129 (2007) (quoting Abbott Labs v. MedImmune, Inc.
59 
Let's personalize your content